<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00046228</url>
  </required_header>
  <id_info>
    <org_study_id>CR005410</org_study_id>
    <secondary_id>FINESSE</secondary_id>
    <secondary_id>CR005410</secondary_id>
    <nct_id>NCT00046228</nct_id>
  </id_info>
  <brief_title>A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)</brief_title>
  <official_title>A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centocor, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether abciximab given in combination with
      reteplase, before patients have a coronary intervention (a standard treatment where a
      catheter is inserted into the heart artery to get blood flowing past the clot), is safe and
      effective in the treatment of heart attacks compared to only abciximab given during coronary
      intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this medical research study is to determine whether abciximab given in
      combination with reteplase, before patients have a coronary intervention (a standard
      treatment where a catheter is inserted into the heart artery to get blood flowing past the
      clot), is safe and effective in the treatment of heart attacks compared to only abciximab
      given during coronary intervention. This medical research study will also help determine if
      the combination of abciximab and reduced dose reteplase will decrease the risk of death, and
      reduce complications of a heart attack at 90 days compared to abciximab alone which is a
      standard treatment.

      Patients will receive either abciximab and reteplease or abciximab alone. Safety evaluations
      will be performed at specified intervals throughout the study and will consist of laboratory
      tests, vital signs (such as blood pressure), physical examinations and the occurrence and
      severity of adverse events as well as other study specific procedures. Patients will receive
      either abciximab and reteplease or abciximab and placebo into a vein in their arm for up to
      12 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Composite of All-Cause Mortality or Complications of MI at 90 Days.</measure>
    <time_frame>90 days</time_frame>
    <description>Occurs within 90 days and is composite of all-cause mortality or complications of myocardial infarction (MI) (rehospitalization or emergency department visit for congestive heart failure (CHF), cardiogenic shock, or resuscitated ventricular fibrillation occurring &gt; 48 hours after randomization).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications of MI as Defined in the Primary Outcome Measure Through 90 Days</measure>
    <time_frame>90 Days</time_frame>
    <description>The complications of myocardial infarction (MI) is defined as any event of rehospitalization or emergency department visit for CHF, cardiogenic shock, or resuscitated ventricular fibrillation occurring &gt; 48 hours after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-Cause Mortality Through 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>All cause mortality occurred through 90 days from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With ST-Segment Resolution &gt; 70% From Baseline at 60 to 90 Minutes Following Randomization</measure>
    <time_frame>60 to 90 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-Cause Mortality Through 1 Year</measure>
    <time_frame>1 year</time_frame>
    <description>All-cause mortality through 1 year from randomization.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subjects With Intracranial Hemorrhage (Including Hemorrhagic Transformation) Through Discharge/Day 7</measure>
    <time_frame>Discharge/Day 7</time_frame>
    <description>All cases of cerebrovascular event were confirmed by a CEC (Clinical Endpoints Committee).</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjects With Non Intracranial Thrombolysis In Myocardial Infarction (TIMI) Bleeding Events Through Discharge/Day 7</measure>
    <time_frame>Discharge/Day 7</time_frame>
    <description>Subjects with nonintracranial TIMI bleeding (either major or minor) through discharge/day 7, originating from vascular instrumentation sites, non-instrument related bleeding, as well as overall, were examined.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjects With Severe Thrombocytopenia Through Discharge/Day 7</measure>
    <time_frame>Discharge/Day 7</time_frame>
    <description>Severe thrombocytopenia is defined as platelet count &lt; 50,000 cells/μL.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjects With Any Investigator Reported Bleeding Events Through Discharge/Day 7</measure>
    <time_frame>Discharge/Day 7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Subjects With Pre-Specified Complications of Index Myocardial Infarction Through Discharge/Day 7</measure>
    <time_frame>Discharge/Day 7</time_frame>
    <description>Number of subjects with one or more of the following: 2nd or 3rd Degree AVB, Asystole, Sustained V Tach, A Fib/Flutter, EMD/Pulseless Electrical Activity, Heart Failure, Tamponade, Myocardial Rupture, Papillary Muscle Rupture, Ventricular Septal Defect, Pulmonary Embolism, Systemic Arterial Embolism and/or Pericarditis/Pericardial Effusion.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2461</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abciximab; reteplase; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>abciximab; reteplase placebo; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>abciximab placebo; reteplase placebo, abciximab, abciximab placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abciximab placebo; reteplase placebo, abciximab, abciximab</intervention_name>
    <description>placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab; reteplase; abciximab placebo; abciximab</intervention_name>
    <description>0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abciximab; reteplase placebo; abciximab placebo; abciximab</intervention_name>
    <description>0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abciximab placebo; reteplase placebo, abciximab, abciximab</intervention_name>
    <description>placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abciximab; reteplase placebo; abciximab placebo; abciximab</intervention_name>
    <description>0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab; reteplase; abciximab placebo; abciximab</intervention_name>
    <description>0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have prolonged, continuous (lasting at least 20 minutes) signs and
             symptoms of A heart attack not eliminated with nitrates and onset within 6 hours of
             randomization,and confirmation by Electrocardiogram

        Exclusion Criteria:

          -  Low risk clinical presentation

          -  patients who will not be undergoing a catherization within 4 hours of the qualifying
             Electrocardiogram
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Covina</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rock Island</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westlake</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pawtucket</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bremerton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adrogue</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merlo</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Martin</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruck An Der Mur</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deutschlandsberg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eeklo</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herentals</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mechelen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reet</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waregem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmalle</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dimitrovgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haskovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Repentigny</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Benesov U Prahy</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bilovec N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boskovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruntál 1</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruntál</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caslav N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ceske Budejovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cesky Krumlov N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Havíøov 1</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hodonín 1</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hranice 1</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeseník 1</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jicin N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jihlava N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karniva-Ray N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyjov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Most N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novy Jicin N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odry</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisek N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poruba</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10 N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 9</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prerov N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prostejov N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strakonice N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sumperk N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Svitavy N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tabor N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Teplice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trutnov N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tøebíè 1</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tøinec 1</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti Nad Orlici N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valasske Mezirici N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vyskov N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Znojmo N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ústí Nad Labem 11</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Esbjerg N/A</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frederikshavn N/A</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hjÿrring N/A</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Horsens N/A</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kÿbenhavn Nv N/A</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kÿbenhavn Sud N/A</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kÿbenhavn Ÿ</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense N/A</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Randers</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Viborg N/A</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ÿlborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ÿrhus N</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colmar N/A</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy Cedex N/A</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre Les Nancy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Segeberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eschweiler</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Friedberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaltenkirchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meißen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pfaffenhofen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Radebeul</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schönebeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bedzin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bielsko-Biala</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boleslawiec</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brzeg</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Czestochowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdynia Poland</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gliwice N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gorlice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grojec</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jastrzebie-Zdroj</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Konin N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Konskie N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koscierzyna</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nowy Dwor M</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nysa N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Opole N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piotrkow Trybunalski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Radomsko</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ruda Slaska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skierniewice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Swidnica</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tychy N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ustron N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa Poland</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zabrze N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zyrardow N/A</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arcadia Pretoria N/A</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town Western Province</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roodepoort Central Gauteng</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante N/A</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona N/A</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander N/A</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago De Compostela N/A</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg N/A</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Basel N/A</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruderholz N/A</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liestal</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antrim</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chichester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middlesbrough N/A</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portadown</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Leonards On Sea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockton On Tees</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worthing</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=15&amp;filename=CR005410_CSR.pdf</url>
    <description>A Study of Abciximab and Reteplase When Administered Prior to Catheterization After a Myocardial Infarction - Finesse</description>
  </link>
  <results_reference>
    <citation>Ellis SG, Armstrong P, Betriu A, Brodie B, Herrmann H, Montalescot G, Neumann FJ, Smith JJ, Topol E; Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events Investigators. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J. 2004 Apr;147(4):E16.</citation>
    <PMID>15077099</PMID>
  </results_reference>
  <results_reference>
    <citation>Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES, Topol EJ; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008 May 22;358(21):2205-17. doi: 10.1056/NEJMoa0706816.</citation>
    <PMID>18499565</PMID>
  </results_reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2002</study_first_submitted>
  <study_first_submitted_qc>September 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2002</study_first_posted>
  <results_first_submitted>March 26, 2009</results_first_submitted>
  <results_first_submitted_qc>March 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 15, 2009</results_first_posted>
  <last_update_submitted>July 25, 2014</last_update_submitted>
  <last_update_submitted_qc>July 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>abciximab</keyword>
  <keyword>reteplase</keyword>
  <keyword>safety and efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
    <mesh_term>Reteplase</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in 20 countries. The FINESSE (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events) study began enrollment in August 2002. It was planned that approximately 3,000 subjects would be enrolled. Because of enrollment difficulty, subject enrollment was stopped on 30 Dec 2006.</recruitment_details>
      <pre_assignment_details>A total of 2,461 subjects were enrolled in the study according to the sponsor’s clinical trial management system. Out of 2461 subjects, 2,452 subjects were randomly assigned to the 3 treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Primary PCI Group</title>
          <description>Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI)</description>
        </group>
        <group group_id="P2">
          <title>Abciximab Facilitated PCI Group</title>
          <description>Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI</description>
        </group>
        <group group_id="P3">
          <title>Reteplase/Abciximab Facilitated PCI Group</title>
          <description>Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects &lt; 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>90 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="806"/>
                <participants group_id="P2" count="818"/>
                <participants group_id="P3" count="828"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="793">The number completed includes subjects who died or were seen for a visit within specified window.</participants>
                <participants group_id="P2" count="810">The number completed includes subjects who died or were seen for a visit within specified window.</participants>
                <participants group_id="P3" count="813">The number completed includes subjects who died or were seen for a visit within specified window.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>1 Year</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="806">This is the number of participants that were originally randomized to the trial.</participants>
                <participants group_id="P2" count="818">This is the number of participants that were originally randomized to the trial.</participants>
                <participants group_id="P3" count="828">This is the number of participants that were originally randomized to the trial.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="787">The number completed includes subjects who died or were seen for a visit within specified window.</participants>
                <participants group_id="P2" count="804">The number completed includes subjects who died or were seen for a visit within specified window.</participants>
                <participants group_id="P3" count="816">The number completed includes subjects who died or were seen for a visit within specified window</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Primary PCI Group</title>
          <description>Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI)</description>
        </group>
        <group group_id="B2">
          <title>Abciximab Facilitated PCI Group</title>
          <description>Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI</description>
        </group>
        <group group_id="B3">
          <title>Reteplase/Abciximab Facilitated PCI Group</title>
          <description>Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects &lt; 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="806"/>
            <count group_id="B2" value="818"/>
            <count group_id="B3" value="828"/>
            <count group_id="B4" value="2452"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" spread="11.4"/>
                    <measurement group_id="B2" value="61.9" spread="11.8"/>
                    <measurement group_id="B3" value="62.6" spread="11.4"/>
                    <measurement group_id="B4" value="62.4" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="216"/>
                    <measurement group_id="B3" value="219"/>
                    <measurement group_id="B4" value="642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="599"/>
                    <measurement group_id="B2" value="602"/>
                    <measurement group_id="B3" value="609"/>
                    <measurement group_id="B4" value="1810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Composite of All-Cause Mortality or Complications of MI at 90 Days.</title>
        <description>Occurs within 90 days and is composite of all-cause mortality or complications of myocardial infarction (MI) (rehospitalization or emergency department visit for congestive heart failure (CHF), cardiogenic shock, or resuscitated ventricular fibrillation occurring &gt; 48 hours after randomization).</description>
        <time_frame>90 days</time_frame>
        <population>Population is the intent-to-treat subjects. The intent-to-treat population is defined as all subjects randomly assigned to a treatment group and classified according to the randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary PCI Group</title>
            <description>Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI)</description>
          </group>
          <group group_id="O2">
            <title>Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI</description>
          </group>
          <group group_id="O3">
            <title>Reteplase/Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects &lt; 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>The Composite of All-Cause Mortality or Complications of MI at 90 Days.</title>
          <description>Occurs within 90 days and is composite of all-cause mortality or complications of myocardial infarction (MI) (rehospitalization or emergency department visit for congestive heart failure (CHF), cardiogenic shock, or resuscitated ventricular fibrillation occurring &gt; 48 hours after randomization).</description>
          <population>Population is the intent-to-treat subjects. The intent-to-treat population is defined as all subjects randomly assigned to a treatment group and classified according to the randomization assignment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="806"/>
                <count group_id="O2" value="818"/>
                <count group_id="O3" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if reteplase/abciximab facilitated PCI is the same as the primary PCI in terms of the primary efficacy outcome. Assuming the relative risk reduction for the reteplase/abciximab facilitated PCI group versus the Primary PCI group is 15% in lower risk, 25% in medium risk, and 35% in high risk, the power of this comparison (1,000 subjects per group) is 83.4 %.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.551</p_value>
            <p_value_desc>The null hypothesis was tested at the significance level of 0.049. If it is significant, the significance level of null hypotheses tested in the analyses 2 and 3 will be adjusted according to the modified Hochberg approach.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Independent Clinical Endpoints Committee confirmed components of primary endpoint except for death &amp; resuscitated v fib assessed by the investigator)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if abciximab facilitated PCI is the same as the primary PCI in terms of the primary efficacy outcome. Assuming the relative risk reduction for the Abciximab facilitated PCI versus the Primary PCI group is 12.7%, in lower risk, 17.9% in medium risk, and 25.0% in high risk, the power of this comparison (1000 subjects per group) is 54.1%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.858</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if reteplase/abciximab facilitated PCI is the same as the abciximab facilitated PCI in terms of the primary efficacy outcome. Assuming the relative risk reduction for the reteplase/abciximab facilitated PCI versus the abciximab facilitated PCI group is 2.6% in lower risk, 8.7% in medium risk, and 13.3% in high risk, the power of this comparison (1,000 subjects per group) is 13.5%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.676</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications of MI as Defined in the Primary Outcome Measure Through 90 Days</title>
        <description>The complications of myocardial infarction (MI) is defined as any event of rehospitalization or emergency department visit for CHF, cardiogenic shock, or resuscitated ventricular fibrillation occurring &gt; 48 hours after randomization.</description>
        <time_frame>90 Days</time_frame>
        <population>Population is the intent-to-treat subjects. The intent-to-treat population is defined as all subjects that have been randomly assigned to a treatment group and classified according to the randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary PCI Group</title>
            <description>Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI)</description>
          </group>
          <group group_id="O2">
            <title>Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI</description>
          </group>
          <group group_id="O3">
            <title>Reteplase/Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects &lt; 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Complications of MI as Defined in the Primary Outcome Measure Through 90 Days</title>
          <description>The complications of myocardial infarction (MI) is defined as any event of rehospitalization or emergency department visit for CHF, cardiogenic shock, or resuscitated ventricular fibrillation occurring &gt; 48 hours after randomization.</description>
          <population>Population is the intent-to-treat subjects. The intent-to-treat population is defined as all subjects that have been randomly assigned to a treatment group and classified according to the randomization assignment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="806"/>
                <count group_id="O2" value="818"/>
                <count group_id="O3" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if reteplase/abciximab facilitated PCI is the same as the primary PCI in complications of MI within 90 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.247</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if abciximab facilitated PCI is the same as the primary PCI in complications of MI within 90 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.278</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if reteplase/abciximab facilitated PCI is the same as the abciximab facilitated PCI in complications of MI within 90 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.944</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-Cause Mortality Through 90 Days</title>
        <description>All cause mortality occurred through 90 days from randomization.</description>
        <time_frame>90 days</time_frame>
        <population>Population is the intent-to-treat subjects. The intent-to-treat population is defined as all randomized subjects classified according to the randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary PCI Group</title>
            <description>Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI)</description>
          </group>
          <group group_id="O2">
            <title>Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI</description>
          </group>
          <group group_id="O3">
            <title>Reteplase/Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects &lt; 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>All-Cause Mortality Through 90 Days</title>
          <description>All cause mortality occurred through 90 days from randomization.</description>
          <population>Population is the intent-to-treat subjects. The intent-to-treat population is defined as all randomized subjects classified according to the randomization assignment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="806"/>
                <count group_id="O2" value="818"/>
                <count group_id="O3" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if retaplase/abciximab facilitated PCI is the same as the primary PCI in 90-day all cause mortality.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.494</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if abciximab facilitated PCI is the same as the primary PCI in 90-day all cause mortality.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.338</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if retaplase/abciximab facilitated PCI is the same as the abciximab facilitated PCI in 90-day all cause mortality.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.781</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With ST-Segment Resolution &gt; 70% From Baseline at 60 to 90 Minutes Following Randomization</title>
        <time_frame>60 to 90 minutes</time_frame>
        <population>Population is the intent-to-treat subjects who were selected for evaluation by electrocardiogram (ECG) core laboratory.Subjects, who were not evaluable for a 60-90 minute ECG, were considered not having a ST segment resolution.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary PCI Group</title>
            <description>Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI)</description>
          </group>
          <group group_id="O2">
            <title>Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI</description>
          </group>
          <group group_id="O3">
            <title>Reteplase/Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects &lt; 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With ST-Segment Resolution &gt; 70% From Baseline at 60 to 90 Minutes Following Randomization</title>
          <population>Population is the intent-to-treat subjects who were selected for evaluation by electrocardiogram (ECG) core laboratory.Subjects, who were not evaluable for a 60-90 minute ECG, were considered not having a ST segment resolution.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="432"/>
                <count group_id="O3" value="424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if retaplase/abciximab facilitated PCI is the same as the primary PCI in ST-segment resolution &gt;70% from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if abciximab facilitated PCI is the same as the primary PCI in ST-segment resolution &gt;70% from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.670</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if retaplase/abciximab facilitated PCI is the same as the abciximab facilitated PCI in ST-segment resolution &gt;70% from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-Cause Mortality Through 1 Year</title>
        <description>All-cause mortality through 1 year from randomization.</description>
        <time_frame>1 year</time_frame>
        <population>Population is the intent-to-treat subjects. The intent-to-treat population is defined as all randomized subjects classified according to the randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary PCI Group</title>
            <description>Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI)</description>
          </group>
          <group group_id="O2">
            <title>Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI</description>
          </group>
          <group group_id="O3">
            <title>Reteplase/Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects &lt; 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>All-Cause Mortality Through 1 Year</title>
          <description>All-cause mortality through 1 year from randomization.</description>
          <population>Population is the intent-to-treat subjects. The intent-to-treat population is defined as all randomized subjects classified according to the randomization assignment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="806"/>
                <count group_id="O2" value="818"/>
                <count group_id="O3" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.603</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.765</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.415</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjects With Intracranial Hemorrhage (Including Hemorrhagic Transformation) Through Discharge/Day 7</title>
        <description>All cases of cerebrovascular event were confirmed by a CEC (Clinical Endpoints Committee).</description>
        <time_frame>Discharge/Day 7</time_frame>
        <population>The population was defined as all subjects who were randomized and treated with any study agent, including those who discontinued for any reasons. Subjects randomized and treated was classified according to the study drug(s) received.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary PCI Group</title>
            <description>Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI)</description>
          </group>
          <group group_id="O2">
            <title>Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI</description>
          </group>
          <group group_id="O3">
            <title>Reteplase/Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects &lt; 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Intracranial Hemorrhage (Including Hemorrhagic Transformation) Through Discharge/Day 7</title>
          <description>All cases of cerebrovascular event were confirmed by a CEC (Clinical Endpoints Committee).</description>
          <population>The population was defined as all subjects who were randomized and treated with any study agent, including those who discontinued for any reasons. Subjects randomized and treated was classified according to the study drug(s) received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="795"/>
                <count group_id="O2" value="805"/>
                <count group_id="O3" value="814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if reteplase/abciximab facilitated PCI is the same as the primary PCI in the risk of ICH.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.218</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if abciximab facilitated PCI is the same as the primary PCI in the risk of ICH.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.497</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if reteplase/abciximab facilitated PCI is the same as the abciximab facilitated PCI in the risk of ICH.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjects With Non Intracranial Thrombolysis In Myocardial Infarction (TIMI) Bleeding Events Through Discharge/Day 7</title>
        <description>Subjects with nonintracranial TIMI bleeding (either major or minor) through discharge/day 7, originating from vascular instrumentation sites, non-instrument related bleeding, as well as overall, were examined.</description>
        <time_frame>Discharge/Day 7</time_frame>
        <population>The population was defined as all subjects who were randomized and treated with any study agent, including those who discontinued for any reasons. Subjects randomized and treated was classified according to the study drug(s) received.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary PCI Group</title>
            <description>Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI)</description>
          </group>
          <group group_id="O2">
            <title>Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI</description>
          </group>
          <group group_id="O3">
            <title>Reteplase/Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects &lt; 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Non Intracranial Thrombolysis In Myocardial Infarction (TIMI) Bleeding Events Through Discharge/Day 7</title>
          <description>Subjects with nonintracranial TIMI bleeding (either major or minor) through discharge/day 7, originating from vascular instrumentation sites, non-instrument related bleeding, as well as overall, were examined.</description>
          <population>The population was defined as all subjects who were randomized and treated with any study agent, including those who discontinued for any reasons. Subjects randomized and treated was classified according to the study drug(s) received.</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="795"/>
                <count group_id="O2" value="805"/>
                <count group_id="O3" value="814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if reteplase/abciximab facilitated PCI is the same as the primary PCI in the risk of non-ICH TIMI bleeding events.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.63</ci_lower_limit>
            <ci_upper_limit>3.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if abciximab facilitated PCI is the same as the primary PCI in the risk of non-ICH TIMI bleeding events.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is if reteplase/abciximab facilitated PCI is the same as the abciximab facilitated PCI in the risk of non-ICH TIMI bleeding events.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjects With Severe Thrombocytopenia Through Discharge/Day 7</title>
        <description>Severe thrombocytopenia is defined as platelet count &lt; 50,000 cells/μL.</description>
        <time_frame>Discharge/Day 7</time_frame>
        <population>The population was defined as all subjects who were randomized and treated with any study agent, including those who discontinued for any reasons. Subjects randomized and treated was classified according to the study drug(s) received.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary PCI Group</title>
            <description>Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI)</description>
          </group>
          <group group_id="O2">
            <title>Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI</description>
          </group>
          <group group_id="O3">
            <title>Reteplase/Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects &lt; 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Severe Thrombocytopenia Through Discharge/Day 7</title>
          <description>Severe thrombocytopenia is defined as platelet count &lt; 50,000 cells/μL.</description>
          <population>The population was defined as all subjects who were randomized and treated with any study agent, including those who discontinued for any reasons. Subjects randomized and treated was classified according to the study drug(s) received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="795"/>
                <count group_id="O2" value="805"/>
                <count group_id="O3" value="814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.439</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.438</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjects With Any Investigator Reported Bleeding Events Through Discharge/Day 7</title>
        <time_frame>Discharge/Day 7</time_frame>
        <population>The population was defined as all subjects who were randomized and treated with any study agent, including those who discontinued for any reasons. Subjects randomized and treated was classified according to the study drug(s) received.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary PCI Group</title>
            <description>Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI)</description>
          </group>
          <group group_id="O2">
            <title>Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI</description>
          </group>
          <group group_id="O3">
            <title>Reteplase/Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects &lt; 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Any Investigator Reported Bleeding Events Through Discharge/Day 7</title>
          <population>The population was defined as all subjects who were randomized and treated with any study agent, including those who discontinued for any reasons. Subjects randomized and treated was classified according to the study drug(s) received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="795"/>
                <count group_id="O2" value="805"/>
                <count group_id="O3" value="814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="178"/>
                    <measurement group_id="O3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjects With Pre-Specified Complications of Index Myocardial Infarction Through Discharge/Day 7</title>
        <description>Number of subjects with one or more of the following: 2nd or 3rd Degree AVB, Asystole, Sustained V Tach, A Fib/Flutter, EMD/Pulseless Electrical Activity, Heart Failure, Tamponade, Myocardial Rupture, Papillary Muscle Rupture, Ventricular Septal Defect, Pulmonary Embolism, Systemic Arterial Embolism and/or Pericarditis/Pericardial Effusion.</description>
        <time_frame>Discharge/Day 7</time_frame>
        <population>Population is the intent-to-treat subjects. The intent-to-treat population is defined as all randomized subjects classified according to the randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary PCI Group</title>
            <description>Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI)</description>
          </group>
          <group group_id="O2">
            <title>Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI</description>
          </group>
          <group group_id="O3">
            <title>Reteplase/Abciximab Facilitated PCI Group</title>
            <description>Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects &lt; 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Pre-Specified Complications of Index Myocardial Infarction Through Discharge/Day 7</title>
          <description>Number of subjects with one or more of the following: 2nd or 3rd Degree AVB, Asystole, Sustained V Tach, A Fib/Flutter, EMD/Pulseless Electrical Activity, Heart Failure, Tamponade, Myocardial Rupture, Papillary Muscle Rupture, Ventricular Septal Defect, Pulmonary Embolism, Systemic Arterial Embolism and/or Pericarditis/Pericardial Effusion.</description>
          <population>Population is the intent-to-treat subjects. The intent-to-treat population is defined as all randomized subjects classified according to the randomization assignment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="806"/>
                <count group_id="O2" value="818"/>
                <count group_id="O3" value="828"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.434</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.589</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.809</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Primary PCI Group</title>
          <description>Abciximab (bolus + 12 hr infusion) initiated just prior to primary percutaneous coronary intervention (PCI)</description>
        </group>
        <group group_id="E2">
          <title>Abciximab Facilitated PCI Group</title>
          <description>Abciximab (bolus) administered as soon as possible after randomization, 12 hour infusion initiated prior to PCI</description>
        </group>
        <group group_id="E3">
          <title>Reteplase/Abciximab Facilitated PCI Group</title>
          <description>Abciximab (bolus) + reteplase (5 U + 5 U double bolus for subjects &lt; 75 years of age; 5 U single bolus for subjects ≥ 75 years of age), abciximab 12 hour infusion initiated prior to PCI</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>WHOART</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="175" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Anemia microcytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Anemia iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary stenosis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Shock cardiogenic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Unstable angina</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Chronic congestive heart failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Heart disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Myocardial rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Spiral coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Stable angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Tricuspid insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Anginal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Coronary in-stent restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Coronary restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Left ventricular ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Mitral insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Mitral regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Fibrillation ventricular</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Tachycardia ventricular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>AV block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>AV block third degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Junctional bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Nonsustained ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Arrhythmia ventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Asystolia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>AV block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Cardiac arrhythmia nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Cardiac rhythm disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Electromechanical dissociation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Intraventricular conduction defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Tachycardia atrial paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Ventricular bigeminy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Ventricular febrillation paroxysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Atherosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Blood pressure high</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Transient hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Hypertension arterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Hypovolemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Ventricular aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Esophageal reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Intestinal Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Nontropical sprue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Preploric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Digestion impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Stomach upset</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Non-anginal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Non-ischemic chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Allergic reaction to diagnostic agent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Incarcerated abdonimal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Interstitial fluid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Intolerance induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Nontoxic drug overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Gall bladder distention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Hepatobiliary dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Wound healing impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Adult onset diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Aseptic necrosis bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Bone fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Skeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pulmonary cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pulmonary carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Rectal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Ovarian cyst malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Renal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy grand mal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pre-syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Chronic renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Renal function decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Urethral disorder nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Acute renal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Bladder stricture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Aspiration pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Breathing difficult</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Coughing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pleuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Repiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Respiratory tract lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Breathlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pleural exudate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pneumonia interstitial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Breath shortness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>GI hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>GI hemorrhage - upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Hemorrhage nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Hemorrhage rectum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Puncture site hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Retroperitoneal hemorrhage (type unknown)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Vomiting blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Claudication intermittent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Extracardiact arterial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Thrombosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Thrombosis cardiac chamber</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Atheroembolism limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Embolism pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Thrombosis venous deep</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Venous thrombosis leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Left ventricular thrombus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="814"/>
              </event>
              <event>
                <sub_title>Phlebothrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="805"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="814"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Some AEs were collected separately per protocol and are reported as “Other Pre-Specified Outcomes Measures”.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Executive Director Clinical Research</name_or_title>
      <organization>Centocor Inc.</organization>
      <phone>1-800-972-9063 ext 6171</phone>
      <email>EBarnath@ITS.JNJ.COM</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

